偏头痛患者的心理特征不会影响对erenumab的反应。 - Suppr | 超能文献

相似文献

1

Migraineurs' psychological traits do not influence response to erenumab.偏头痛患者的心理特征不会影响对erenumab的反应。

Neurol Sci. 2020 Dec;41(Suppl 2):467-468. doi: 10.1007/s10072-020-04661-6.

2

Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.依瑞奈尤单抗治疗重度治疗抵抗性偏头痛患者：首个德国真实世界证据。

J Headache Pain. 2020 Jul 3;21(1):84. doi: 10.1186/s10194-020-01151-0.

3

Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.依瑞奈尤单抗治疗偏头痛预防性治疗的疗效和安全性的系统评价和荟萃分析。

Drugs. 2019 Mar;79(4):417-431. doi: 10.1007/s40265-019-01069-1.

4

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.依瑞奈单抗：用于偏头痛预防的首创类单克隆抗体。

Ann Pharmacother. 2019 Sep;53(9):933-939. doi: 10.1177/1060028019835166. Epub 2019 Feb 27.

5

Central effects of erenumab in migraine patients: An event-related functional imaging study.依那西普治疗偏头痛患者的中枢作用：一项事件相关功能成像研究。

Neurology. 2020 Nov 17;95(20):e2794-e2802. doi: 10.1212/WNL.0000000000010740. Epub 2020 Sep 11.

6

Erenumab: First Global Approval.依瑞奈尤单抗：全球首次获批。

Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0.

7

Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.在健康受试者和偏头痛患者中进行依瑞奈umab 的 I 期、随机、双盲、安慰剂对照、单次和多次剂量研究。

Clin Pharmacol Ther. 2018 May;103(5):815-825. doi: 10.1002/cpt.799. Epub 2017 Oct 24.

8

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.依瑞奈尤单抗治疗慢性偏头痛患者的反应谱及达到≥50%、≥75%和 100%应答的患者亚组分析。

Cephalalgia. 2020 Jan;40(1):28-38. doi: 10.1177/0333102419894559. Epub 2019 Dec 9.

9

Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab).偏头痛预防治疗药物 Aimovig（依瑞奈尤单抗）识别 CGRPR 复合物的分子机制研究

Cell Rep. 2020 Feb 11;30(6):1714-1723.e6. doi: 10.1016/j.celrep.2020.01.029.

10

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.ARISE：依那西普治疗阵发性偏头痛的 3 期随机试验。

Cephalalgia. 2018 May;38(6):1026-1037. doi: 10.1177/0333102418759786. Epub 2018 Feb 22.

引用本文的文献

1

Psychopathological variables in chronic migraine patients with different therapeutic approach: psychological profile differences and impact on therapeutic efficacy in real life.慢性偏头痛患者采用不同治疗方法的心理病理变量：真实生活中的心理特征差异及对疗效的影响。

Neurol Sci. 2024 Dec;45(12):5813-5821. doi: 10.1007/s10072-024-07769-1. Epub 2024 Sep 19.

2

Real-life experiences with galcanezumab and predictors for treatment response in Turkey.土耳其使用加奈珠单抗的真实体验及其治疗反应的预测因素。

BMC Neurol. 2023 Nov 23;23(1):418. doi: 10.1186/s12883-023-03467-1.

3

Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine.